Medicare utilization — WAYNE GERALD RISKIN (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | 9,000 | 128 | $0 | $160,975 |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6,434 | 18 | $0 | $216,238 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4,941 | 18 | $0 | $131,265 |
| J9250 | Methotrexate sodium, 5 mg | 1,164 | 19 | $0 | $217 |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 787 | 339 | $0 | $72,111 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·